Quality of Life — ERANet-LAC CODE: International Care Of the Dying Evaluation
Citation(s)
Burge F, Lawson B, Johnston G, Asada Y, McIntyre PF, Grunfeld E, Flowerdew G Bereaved family member perceptions of patient-focused family-centred care during the last 30 days of life using a mortality follow-back survey: does location matter? BMC Palliat Care. 2014 May 14;13:25. doi: 10.1186/1472-684X-13-25. eCollection 2014.
Department of Health (2008) End of life care strategy. Promoting high quality care for all adults at the end of life. Department of Health: London.
Germain A, Mayland CR, Jack BA The potential therapeutic value for bereaved relatives participating in research: An exploratory study. Palliat Support Care. 2016 Oct;14(5):479-87. doi: 10.1017/S1478951515001194. Epub 2015 Oct 29.
Malterud K Systematic text condensation: a strategy for qualitative analysis. Scand J Public Health. 2012 Dec;40(8):795-805. doi: 10.1177/1403494812465030.
Mayland C, Williams E, Ellershaw J How well do current instruments using bereaved relatives' views evaluate care for dying patients? Palliat Med. 2008 Mar;22(2):133-44. doi: 10.1177/0269216307085742.
Mayland C User-guide for 'Care of the Dying Evaluation' (CODETM). The Marie Curie Palliative Care Institute Liverpool, 2015.
Mayland CR, Keetharuth AD, Mukuria C, Haugen DF Validation of 'Care Of the Dying Evaluation' (CODETM) within an international study exploring bereaved relatives' perceptions about quality of care in the last days of life. J Pain Symptom Manage. 2022 Jul;
Mayland CR, Mulholland H, Gambles M, Ellershaw J, Stewart K How well do we currently care for our dying patients in acute hospitals: the views of the bereaved relatives? BMJ Support Palliat Care. 2017 Sep;7(3):316-325. doi: 10.1136/bmjspcare-2014-000810. Epub 2017 Jan 17.
Mayland CR, Williams EM, Addington-Hall J, Cox TF, Ellershaw JE Assessing the quality of care for dying patients from the bereaved relatives' perspective: further validation of "Evaluating care and health outcomes--for the dying". J Pain Symptom Manage. 2014 Apr;47(4):687-96. doi: 10.1016/j.jpainsymman.2013.05.013. Epub 2013 Nov 5.
Mayland CR, Williams EM, Addington-Hall J, Cox TF, Ellershaw JE Does the 'Liverpool Care Pathway' facilitate an improvement in quality of care for dying cancer patients? Br J Cancer. 2013 May 28;108(10):1942-8. doi: 10.1038/bjc.2013.203. Epub 2013 May 16.
Mayland CR, Williams EM, Ellershaw JE Assessing quality of care for the dying: the development and initial validation of a postal self-completion questionnaire for bereaved relatives. Palliat Med. 2012 Oct;26(7):897-907. doi: 10.1177/0269216311424953. Epub 2011 Nov 1.
Pastrana T, Eisenchlas J, Centeno C, De Lima L Status of palliative care in Latin America: looking through the Latin America Atlas of Palliative Care. Curr Opin Support Palliat Care. 2013 Dec;7(4):411-6. doi: 10.1097/SPC.0000000000000008.
Stiel S, Heckel M, Bussmann S, Weber M, Ostgathe C End-of-life care research with bereaved informal caregivers--analysis of recruitment strategy and participation rate from a multi-centre validation study. BMC Palliat Care. 2015 May 2;14:21. doi: 10.1186/s12904-015-0020-4.
The 2015 Quality of Death index Ranking palliative care across the world. The Economist Intelligence Unit. A report by The Economist Intelligence Unit. Lien Foundation 2015.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
